NUVL Stock Price, Nuvalent, Inc. Quote, Chart

Market Summary

USD66.86+0.79

Market Closed

1.20%

NUVL Alerts

5 major insider sales recently.

NUVL Stock Price

View Fullscreen

NUVL RSI Chart

NUVL Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

-30.48

Price/Sales (Trailing)

270.05

Price/Free Cashflow

-38.57

NUVL Price/Sales (Trailing)

NUVL Profitability

Return on Equity

-18.02%

Return on Assets

-17.23%

Free Cashflow Yield

-2.59%

NUVL Fundamentals

NUVL Revenue

Revenue (TTM)

14.0M

Rev. Growth (Yr)

664.58%

Rev. Growth (Qtr)

3.34%

NUVL Earnings

Earnings (TTM)

-126.2M

Earnings Growth (Yr)

-46.58%

Earnings Growth (Qtr)

-13.81%

Breaking Down NUVL Revenue

Last 7 days

4.9%

Last 30 days

-12.7%

Last 90 days

-13.3%

Trailing 12 Months

88.1%

How does NUVL drawdown profile look like?

NUVL Financial Health

Current Ratio

22.83

NUVL Investor Care

Shares Dilution (1Y)

17.22%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2023	9.1M	14.0M	0
2022	1.5M	2.9M	4.3M
2021	0	0	114.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nuvalent, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 22, 2024	shair matthew	sold	-2,386,910	63.6509	-37,500	-
Apr 15, 2024	conley emily	sold	-327,607	65.5214	-5,000	-
Apr 15, 2024	conley emily	acquired	46,800	9.36	5,000	-
Apr 15, 2024	shair matthew	sold	-2,458,340	65.5556	-37,500	-
Apr 08, 2024	shair matthew	sold	-2,566,480	68.4394	-37,500	-
Apr 04, 2024	miller deborah ann	sold	-220,787	73.5957	-3,000	chief legal officer
Apr 04, 2024	miller deborah ann	acquired	20,670	6.89	3,000	chief legal officer
Apr 01, 2024	shair matthew	sold	-2,884,340	76.9156	-37,500	-
Mar 28, 2024	miller deborah ann	acquired	496,740	22.5791	22,000	chief legal officer
Mar 28, 2024	miller deborah ann	sold	-1,654,310	75.196	-22,000	chief legal officer

Which funds bought or sold NUVL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.28	-383,829	8,403,850	-%
Apr 25, 2024	Lindbrook Capital, LLC	new	-	5,632	5,632	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	reduced	-4.04	-8,319	390,318	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	27,000	1,303,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.23	-213,000	68,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	352,172	352,172	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	9.67	443,996	1,031,580	0.01%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-103,000	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	9.24	17,261	167,826	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	13.78	35,077	252,903	0.01%

Are Funds Buying or Selling NUVL?

Are funds buying NUVL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NUVL

No. of Funds

NUVL Alerts

5 major insider sales recently.

Unveiling Nuvalent, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 29, 2024	bain capital life sciences fund ii, l.p.	4.1%	2,400,630	SC 13D/A
Feb 14, 2024	paradigm biocapital advisors lp	6.7%	3,858,008	SC 13G/A
Feb 14, 2024	fairmount funds management llc	3.4%	1,924,626	SC 13G/A
Feb 13, 2024	vanguard group inc	5.72%	3,339,850	SC 13G
Feb 12, 2024	flynn james e	35.01%	25,477,776	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 02, 2024	perceptive advisors llc	5.1%	2,917,991	SC 13G
Oct 30, 2023	paradigm biocapital advisors lp	5.9%	3,379,080	SC 13G
Oct 20, 2023	bain capital life sciences fund ii, l.p.	4.2%	2,400,630	SC 13D/A
Feb 14, 2023	fairmount funds management llc	5.47%	2,788,981	SC 13G/A

Recent SEC filings of Nuvalent, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	SC 13D/A	13D - Major Acquisition
Mar 28, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Nuvalent, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Nuvalent, Inc. News

Latest updates

Nuvalent, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2021Q4
Revenue	3.3%	5,138	4,972	3,176	672	267	-
Operating Expenses	13.9%	38,783	34,062	29,299	20,388	18,733	17,378
S&GA Expenses	12.7%	9,172	8,140	6,444	5,763	5,175	4,184
R&D Expenses	14.2%	29,611	25,922	22,855	14,625	13,558	13,194
Net Income	-15.7%	-33,645	-29,090	-26,123	-19,716	-18,466	-17,289
Net Income Margin	65.3%	-8.17*	-23.55*	-19.25*	-22.68*	-30.10*	-406.47*
Free Cashflow	-3.8%	-22,981	-22,135	-17,779	-18,175	-15,475	-12,955

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	72.3%	732	425	442	461	482	250	263	277	294	308	144	-
Current Assets	73.1%	726	420	437	456	478	245	259	274	291	305	139	11.00
Cash Equivalents	279.3%	335	88.00	71.00	90.00	242	76.00	76.00	67.00	69.00	246	139	10.00
Liabilities	9.3%	32.00	29.00	21.00	17.00	19.00	13.00	10.00	8.00	9.00	7.00	6.00	7.00
Current Liabilities	9.3%	32.00	29.00	21.00	17.00	19.00	13.00	10.00	8.00	9.00	7.00	6.00	4.00
Shareholder's Equity	76.9%	701	396	421	444	463	237	253	269	285	301	-	-
Retained Earnings	-15.4%	-286	-248	-214	-185	-160	-133	-114	-95.80	-78.22	-60.90	-48.51	-31.88
Additional Paid-In Capital	52.9%	987	645	637	630	624	371	368	366	363	362	1.00	1.00
Shares Outstanding	2.3%	58.00	57.00	57.00	57.00	50.00	48.00	48.00	48.00	22.00	13.00	3.00	3.00
Float	-	-	-	1,100	-	-	-	239	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-31.5%	-30,209	-22,981	-22,135	-24,414	-17,779	-18,175	-15,475	-13,542	-12,955	-11,400	-9,712	-5,933	-	-	-
Share Based Compensation	9.3%	7,490	6,854	5,848	5,371	3,017	2,654	2,449	2,205	1,388	1,373	725	65.00	-	-	-
Cashflow From Investing	-246.5%	-56,261	38,400	1,594	-127,260	-65,401	17,567	24,112	13,057	-163,461	-56,567	-	-	-	-	-
Cashflow From Financing	15458.7%	333,423	2,143	1,298	-17.00	248,673	1,006	5.00	-768	-944	174,934	134,232	10,000	-	-	-

NUVL Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 113,243	$ 63,731
General and administrative	36,249	22,377
Total operating expenses	149,492	86,108
Loss from operations	(149,492)	(86,108)
Other income (expense):
Interest income and other income (expense), net	23,273	4,254
Total other income (expense), net	23,273	4,254
Net loss	$ (126,219)	$ (81,854)
Net loss per share attributable to common stockholders, basic	$ (2.17)	$ (1.65)
Net loss per share attributable to common stockholders, diluted	$ (2.17)	$ (1.65)
Weighted average shares of common stock outstanding, basic	58,223,339	49,668,864
Weighted average shares of common stock outstanding, diluted	58,223,339	49,668,864
Comprehensive loss:
Net loss	$ (126,219)	$ (81,854)
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities	525	(266)
Comprehensive loss	$ (125,694)	$ (82,120)

NUVL Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 335,387	$ 241,806
Marketable securities	384,518	230,357
Prepaid expenses and other current assets	6,583	5,828
Total current assets	726,488	477,991
Other assets	5,896	4,468
Total assets	732,384	482,459
Current liabilities:
Accounts payable	9,274	7,195
Accrued expenses	22,549	12,286
Total current liabilities	31,823	19,481
Total liabilities	31,823	19,481
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Additional paid-in capital	986,819	623,543
Accumulated other comprehensive loss	31	(494)
Accumulated deficit	(286,296)	(160,077)
Total stockholders' equity	700,561	462,978
Total liabilities and stockholders' equity	732,384	482,459
Common Class A [Member]
Stockholders' equity:
Common stock	6	5
Common Class B [Member]
Stockholders' equity:
Common stock	$ 1	$ 1

About Nuvalent, Inc.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase Ã‚Â½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. James R. Porter Ph.D.
WEBSITE	nuvalent.com
INDUSTRY	Biotechnology
EMPLOYEES	78

Nuvalent, Inc. Frequently Asked Questions

What is the ticker symbol for Nuvalent, Inc.? What does NUVL stand for in stocks?

NUVL is the stock ticker symbol of Nuvalent, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvalent, Inc. (NUVL)?

As of Thu Apr 25 2024, market cap of Nuvalent, Inc. is 3.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NUVL stock?

You can check NUVL's fair value in chart for subscribers.

What is the fair value of NUVL stock?

You can check NUVL's fair value in chart for subscribers. The fair value of Nuvalent, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nuvalent, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NUVL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nuvalent, Inc. a good stock to buy?

The fair value guage provides a quick view whether NUVL is over valued or under valued. Whether Nuvalent, Inc. is cheap or expensive depends on the assumptions which impact Nuvalent, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUVL.

What is Nuvalent, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, NUVL's PE ratio (Price to Earnings) is -30.48 and Price to Sales (PS) ratio is 270.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVL PE ratio will change depending on the future growth rate expectations of investors.